IL-2R is made up of three subunits: IL-2Rα (CD25), IL-2Rβ (CD122) and common γc (CD132). The three receptor chains can assemble in multiple configurations and sequences to form low, moderate ...

Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially ...

Three subunits of the IL-2 receptor are available — α chain (CD25), β chain (CD122) and γ chain (CD132). IL-2 and IL-15 receptor complexes share the β and γ chains, and the γ chain is used ...

Second Quarter 2024 Business Highlights "Forte continues to make excellent progress with FB102, our anti-CD122 monoclonal antibody therapeutic candidate. The SAD/MAD phase 1 healthy volunteer ...

To schedule a one-on-one investor meeting with Dr. Fahar Merchant, please register for the conference or contact your H.C. Wainwright representative.

Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby ...

The interleukin-2 receptor (IL-2R) is composed of three different subunits, IL-2Rα (CD25), IL-2Rβ (CD122) and IL-2Rγ (CD132). The complete receptor is usually found on regulatory T (Treg ...

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...

Forte Biosciences, Inc. ( www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024 ...